We are live on ! Find out more

VistaGen Therapeutics

VTGN

Market cap $9.17M

0.2066 USD

-0.0082

3.82%

At close Updated Oct 14, 4:00 PM EDT

Pre-market

After hours

0.1901

-0.0165

7.99%

1 day

-3.82%

5 days

-16.12%

1 month

-15.05%

3 months

-16.05%

6 months

-65.57%

Year to date

-69.57%

1 year

-94.85%

5 years

-99.72%

10 years

-99.84%

About: Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Employees: 41

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 75%

Negative 12.5%

Schaeffers Research

2 Falling Stocks Call Traders Are Targeting Today

Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.

2 Falling Stocks Call Traders Are Targeting Today

Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder

Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans.

Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data

Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for acute social anxiety disorder.

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at Psych Congress 2026

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

Vistagen to Present at Psych Congress 2026

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder.

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population.

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

See News Rankings

Price charts implemented using Lightweight Charts™